Skip to main content
. 2022 Nov 23;14(12):2568. doi: 10.3390/pharmaceutics14122568

Figure 4.

Figure 4

(A) Dissolution profile of niclosamide ASD granules (280 mg), Capsuline, and Eudracap capsules (400 mg of 25% sodium bicarbonate, 5% Explotab®, and 70% ASD) (n = 3); (B) pH-shift dissolution test of the Capsuline and Eudracap capsule formulation; (C) WAXS data of filling material contained in the Capsuline and Eudracap capsules after exposure for 2 h in 0.1 N HCl; (D) acid uptake test of the capsules after 2 h in 0.1 N HCl.